Demand for GLP-1 weight-loss drugs is rising across Great Britain driven by increasing obesity, updated clinical guidelines, wider NHS access and growing public awareness.

Using weight loss drugs is a personal decision that should be made based on informed discussions with healthcare providers ...

A network meta-analysis of nine randomized controlled trials found that once-weekly semaglutide showed the largest estimated ...

Public interest in obesity medication has risen 25-fold since the launch of GLP-1 receptor agonist drugs, new research presented at the International Congress on Obesity (ICO2026) in Mexico City, ...

Medicare previously covered GLP-1s only if the beneficiary also had a condition such as diabetes, sleep apnea, high blood pressure or heart disease.

While two-thirds of large companies cover the expensive medications for weight management, many may drop that coverage in ...

Millions of people could meet criteria to receive GLP-1s, which could cost Medicare billions of dollars, according to a ...

New GLP-1 weight-loss pills from Novo Nordisk and Eli Lilly are likely to boost consumer demand, but employer-sponsored ...

As GLP-1 obesity treatments spread in Korea, they are driving new demand for slimmer clothing, hair care products and ...

Today, Shoppers Drug Mart and Obesity Canada announced a new collaboration focused on advancing awareness of obesity as a chronic disease, reducing weight bias and stigma, and helping more Canadians ...